Economic Impact Of Atopic Dermatitis In Adults: A Population Study (Idea Study)

Mainar, Antoni Sicras; Carrascosa, J.M.; Navarro‐Artieda, Ruth

doi:10.1016/j.jval.2017.08.559

Cited by 6 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The studies were published from 1975 to 2019. Nineteen (37%) were cohort studies, 41,44–46,48,49,52,56–59,67,71,74,82–84,86,89 16 (31%) were cross‐sectional, 22,35,39,51,60,62,64–66,69,70,73,76,77,90,91 eight (16%) were randomized control trials, 50,53–55,61,72,85,88 seven (14%) were case–control studies 43,47,68,75,78,80,87 and one (2%) was a crossover study 63 . The studies were conducted in Europe ( n = 30), 43,44,47–55,57–59,63,68,69,72–75,77,80,83–87,89,91 Asia ( n = 12), 41,56,60–62,65–67,71,76,82,83 North America ( n = 9) 22,35,39,45,46,64,70,78,90 and internationally ( n = 1) 88 .…”

Section: Resultsmentioning

confidence: 99%

“…In total, 2355 nonduplicate articles were identified in the database search, of which 2225 were excluded during title and abstract review, and 79 excluded during full‐text review. Fifty‐one studies were included in this systematic review 22,35,39,41,43–89 (Figure 1) and 19 had sufficient data for inclusion in the quantitative meta‐analyses 22,35,39,43,45,46,51,62,64,66,70,73–76,78,80,82,90 …”

Section: Resultsmentioning

confidence: 99%

“…88 Thirty (59%) included adults, 35,39,41,45,46,48,[50][51][52][53][54]59,62,63,65,66,[68][69][70][71]73,74,76,[83][84][85][86][87][88]90 seven (14%) children, 22,43,47,55,58,78,89 nine (18%) children and adults 44,49,56,61,67,72,75,82,91 and five (10%) with unspecified age range. 57,60,64,77,80 Nineteen studies included > 50% females,…”

Section: Study Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Association between atopic dermatitis and hypertension: a systematic review and meta‐analysis*

et al. 2021

View full text Add to dashboard Cite

Background Previous studies have found conflicting results about the association of atopic dermatitis (AD) with hypertension. Objectives To determine whether AD and AD severity are associated with hypertension. Methods A systematic review was performed of published studies in Ovid MED-LINE, Embase, Scopus, Web of Science, and GREAT (Global Resource for EczemA Trials) databases. At least two reviewers conducted title/abstract, full-text review and data extraction. Quality of evidence was assessed using the Newcastle-Ottawa Scale.Results Fifty-one studies met the inclusion criteria and 19 had sufficient data for meta-analysis. AD was associated with higher odds of hypertension compared with healthy controls [increased in nine of 16 studies; pooled prevalence 16Á4% vs. 13Á8%; random-effects regression, pooled unadjusted odds ratio (OR) 1Á16, 95% confidence interval (CI) 1Á04-1Á30], but lower odds of hypertension compared with psoriasis [decreased in five of eight studies; 15Á4% vs. 24Á8% (OR 0Á53, 95% CI 0Á37-0Á76)]. In particular, moderate-to-severe AD was associated with hypertension compared with healthy controls [increased in four of six studies; 24Á9% vs. 14Á7% (OR 2Á33, 95% CI 1Á10-4Á94)]. Hypertension was commonly reported as an adverse event secondary to AD treatments, particularly systemic ciclosporin A. Limitations include lack of longitudinal studies or individual-level data, and potential confounding. Conclusions AD, particularly moderate-to-severe disease, was associated with increased hypertension compared with healthy controls, but with lower odds than for psoriasis.What is already known about this topic?• Previous studies have showed conflicting results regarding the association between atopic dermatitis (AD) and hypertension.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Association between atopic dermatitis and hypertension: a systematic review and meta‐analysis*

et al. 2021

View full text Add to dashboard Cite

show abstract

“…For Spain, a recent study based on a review of registries of patients with AE seeking healthcare calculated direct and indirect costs as an overall mean of €1,504 per patient per year. Specifically for patients with mild, moderate and severe AE, they calculated €885, €2,111 and €3,397, respectively, per patient per year (22). None of these studies, however, included the out-of-pocket costs of individual patients.…”

Section: Discussionmentioning

confidence: 99%

Out-of-pocket Costs for Individuals with Atopic Eczema: A Cross-sectional Study in Nine European Countries

Zink¹,

Arents²,

Fink-Wagner³

et al. 2019

Acta Derm Venerol

101

View full text Add to dashboard Cite

SIGNIFICANCEAtopic eczema is a skin disease with a huge impact on the everyday lives of affected patients' and their families, but little awareness in the general population. This study including 1,189 people with atopic eczema living in 9 Euro pean countries found that extra out-of-pocket spending due to the atopic eczema is another setback with a mean amount of €927 spent by every patient per year. Out-of-pocket costs are a substantial burden in atopic eczema and much higher than in other chronic diseases. These costs should always be taken into account in individual as well as economic assessments of the disease.Atopic eczema is one of the most common non-communicable inflammatory skin diseases, and has a huge socioeconomic impact. Studies on the everyday economic impact of atopic eczema on patients, however, are limited. To estimate the annual extra out-of-pocket spending due to atopic eczema among patients in Europe, a cross-sectional study using computer-assisted phone interviewing of patients with atopic eczema was performed in 9 European countries. A total of 1,189 patients (56% women) with atopic eczema, who were either eligible for, or on, systemic treatment, participated in the study between October 2017 and March 2018. Mean extra spending on everyday necessities was €927 per patient per year for healthcare expenses, and this figure was slightly, but not statistically significantly, influenced by the severity of atopic eczema. Emollients and moisturizers accounted for the highest monthly costs, followed by medication that was not reimbursed, doctors' and hospital costs. Atopic eczema-related out-of-pocket costs pose a substantial burden for affected individuals, are higher than in other chronic diseases, and should always be included in economic assessments of the impact of this disease.

show abstract

“…These findings provide an indication of the potential societal burden of AD due to productivity losses. It is expected that the introduction of new, effective therapies, such as dupilumab, will reduce the burden of the disease and will lower costs caused by the absence from work and reduced productivity while at work (27)(28)(29)(30).…”

Section: Discussionmentioning

confidence: 99%

Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment

Ariëns¹,

Nimwegen²,

Shams³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

Given the introduction of new therapies targeting specific immune pathways for atopic dermatitis, information on the economic burden of patients with atopic dermatitis is needed. In 90 adult patients with atopic dermatitis indicated for systemic treatment, direct costs (including medication use and healthcare resource utilization) and costs due to reduced work productivity were calculated. Total costs (including directs and costs of productivity loss) were €15,231 per patient per year for the total group and €20,695 for patients with uncontrolled disease vs. €11,287 for patients with controlled disease. Costs of productivity loss had the larger impact on total costs. These data indicate that patients with atopic dermatitis using systemic immunosuppressive treatment incur considerable direct costs and costs of productivity loss. Given the introduction of new therapies targeting specific immune pathways for atopic dermatitis (AD), information on the economic burden of AD patients is needed. Direct costs (medication use and healthcare resource utilization) and costs of productivity loss were studied in 90 adult patients with AD indicated for systemic treatment. Costs were calculated for patients with controlled (Investigator Global Assessment (IGA) 0-2) and uncontrolled (IGA 3-5) disease at inclusion. Mean (95% confidence interval (95% CI)) total direct costs were €5,191 (€4,382-6,019) per patient per year (PPY), €4,401 (€3,695-5,215) for patients with controlled AD vs. €6,993 (€5,552-8,406), mean difference €2,593 (€820-4,282) (p=0.014) for patients with uncontrolled AD. Costs of productivity loss were €10,040 (€6,260-14,012) PPY for the total group, €6,886 (€4,188-10,129) PPY for patients with controlled AD vs. €13,702 (€6,124-22,996) for patients with uncontrolled AD, mean difference €6,816 (-€1,638-16,677; p=0.148). Total costs (direct costs+costs of productivity loss) were €15,231 (€11,487-19,455) PPY for the total group, €11,287 (€7,974-15,436) for patients with controlled AD vs. €20,695 (€14,068-34,564), mean difference €9,408 (-€119-19,964) (p=0.077) for patients with uncontrolled AD. Patients with AD using systemic immunosuppressive treatment incur considerable direct costs and costs of productivity loss.

show abstract

Economic Impact Of Atopic Dermatitis In Adults: A Population Study (Idea Study)

Abstract: In this study, the direct medical cost of UC treatment in Japan was estimated. As the UC is a lifelong disease that appears mainly in young adults, the economic impact including productivity loss is expected to be even greater.

Cited by 6 publications

References 0 publications

Association between atopic dermatitis and hypertension: a systematic review and meta‐analysis*

Association between atopic dermatitis and hypertension: a systematic review and meta‐analysis*

Out-of-pocket Costs for Individuals with Atopic Eczema: A Cross-sectional Study in Nine European Countries

Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment

Contact Info

Product

Resources

About